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The fast and sensitive determination of concentrations of anticancer drugs in specific organs 
can improve the efficacy of chemotherapy and minimize its adverse effects. In this paper, ex 
vivo solid-phase microextraction (SPME) coupled to LC-MS/MS as a method for rapidly 
quantitating doxorubicin (DOX) in lung tissue was optimized. Furthermore, the theoretical 
and practical challenges related to the real-time monitoring of DOX levels in the lung tissue 
of a living organism (in vivo SPME) are presented. In addition, several parameters for ex 
vivo/in vivo SPME studies, such as extraction efficiency of autoclaved fibers, 
intact/homogenized tissue differences, critical tissue amount, and the absence of an internal 
standard are thoroughly examined. To both accurately quantify DOX in solid tissue and 
minimize the error related to the lack of an internal standard, a calibration method at 
equilibrium conditions was chosen. In optimized ex vivo SPME conditions, the targeted 
compound was extracted by directly introducing a 15 mm (45 µm thickness) mixed-mode 
fiber into 15 g of homogenized tissue for 20 min, followed by a desorption step in an optimal 
solvent mixture. The detection limit for DOX was 2.5 µg·g
-1
 of tissue. The optimized ex vivo 
SPME method was successfully applied for the analysis of DOX in real pig lung biopsies, 
providing an averaged accuracy and precision of 103.2% and 12.3%, respectively. 
Additionally, a comparison between SPME and solid-liquid extraction revealed good 
agreement. The results presented herein demonstrate that the developed SPME method 
radically simplifies the sample preparation step and eliminates the need for tissue biopsies. 
These results suggest that SPME can accurately quantify DOX in different tissue 
compartments and can be potentially useful for monitoring and adjusting drug dosages during 
chemotherapy in order to achieve effective and safe concentrations of doxorubicin. 
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 The real-time monitoring of intracellular anticancer drug concentrations and their 
biodistribution in targeted organs aims to enhance the effectiveness of applied chemotherapy 
while reducing detrimental side effects. Doxorubicin (DOX) is a therapeutically relevant 
anthracycline drug that exhibits antitumor activity against a variety of solid tumors, including 
lung, ovarian, and breast cancer [1]. DOX’s cytotoxicity mechanism is based on intercalation 
with DNA, the inhibition of topoisomerase II, and the formation of free radicals, which results 
in DNA damage, oxidative stress, and, ultimately, the death of the cancerous cells [2]. Despite 
these advantages, doxorubicin’s clinical application is limited due to its tendency to produce 
severe adverse dose-dependent systemic and local effects. Consequently, different drug 
delivery systems [3,4] and novel procedures, such as in vivo lung perfusion (IVLP) [5], have 
been introduced in order to reduce DOX’s toxicity and to provide a method for safely 
administering higher doses to targeted organs. However, to precisely assess the concentration 
level and biodistribution of DOX in different tissue compartments, fast, simple, and sensitive 
methods need to be implemented in order to avoid insufficient or excessive dosing. 
 Researchers have used several analytical methods to determine doxorubicin levels in 
biological samples, including liquid chromatography coupled to mass spectrometry (LC-MS) 
[6–9], electrophoresis with laser- or LED-induced fluorescence detection [10,11], and UV 
fluorescence spectroscopy [12]. Furthermore, the use of different sampling/sample-
preparation protocols prior to DOX analysis in solid tissues has also been reported [8,13,14]. 
However, most of these techniques are based on traditional solid-liquid extractions. These 
traditional methods use large amounts of solvents, are time-consuming, and require the 
collection of tissue samples. Moreover, the proposed assays are unable to provide spatial 
resolution as they are performed on biopsy samples collected from terminal parts of the organ 
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[8,15]. To overcome these issues, solid-phase microextraction (SPME) has been introduced as 
a minimally invasive technology that both integrates the sampling, extraction, clean-up, and 
enrichment steps, and also allows for the repeated sampling of different compartments of the 
tissues and organs [16–19]. Additionally, it is important to highlight the fact that SPME 
sampling does not require sample collection; instead, the fiber containing the extraction phase 
is inserted directly into the untreated living tissue. In this way, SPME is a unique technique 
for in vivo drug monitoring because it does not disturb the studied system’s chemical 
equilibria or molecular pathways [17,20,21] as a result of negligible depletion [22]. 
Fundamentally, the principles of SPME extraction can either be based on the equilibrium 
established between the analyte concentrations in the biological matrix and the extraction 
phase, or on extraction under pre-equilibrium conditions.. Therefore, the selection of an 
appropriate calibration model for either ex vivo or in vivo SPME allows for the determination 
of a given drug’s free concentration. In the specific challenge of tissue sampling, a number of 
physiological factors, such as blood flow or temperature, may affect accuracy and precision 
when measuring analyte concentrations in a living organism. The first strategy, equilibrium 
extraction, was initially implemented by Es-haghi et al [23] for in vivo blood pharmacokinetic 
studies of diazepam in dogs. Essentially, since the matrix studied was a biofluid, the 
equilibrium was accelerated by adding forced convection and by recirculating the blood at a 
constant flow. Despite this approach is reliable and practical, it is limited to liquid in vivo 
sampling. The second strategy, diffusion-based calibration, is mainly governed by the mass-
transfer rate at pre-equilibrium conditions. With diffusion-based calibration, it should be noted 
that all physiological and experimental parameters must stay constant to control the thickness 
of the boundary layer over the extraction time during in vivo analysis [16,23–25]. Hence, this 
approaches usually need the introduction of an internal standard to correct for potential 
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extraction condition changes during the procedure [25–28]. For instance, Bai et al [16] 
reported the determination of off-flavor components in live fish using predetermined ex vivo 
sampling rate calibration as well as on fiber standardization. However, it is not always 
allowed to introduce an exogenous compound -internal standard- in the living system and, 
consequently, this approach tends to exhibit some weaknesses. Once the free concentration 
has been determined, it becomes possible to obtain accurate information about the drug’s 
unbound fraction in the analyzed matrix [25,29]. Although the application of in vivo SPME 
sampling in animal models has previously been reported [17,30,31], several theoretical 
considerations related to challenges associated with in vivo SPME studies in humans and 
other clinical applications have yet to be discussed thoroughly. 
 Before DOX in a living system can be accurately quantified, multiple steps of method 
optimization and validation must be performed using external matrices (ex vivo SPME). For 
instance, it is necessary to determine how sterilized SPME probes influence extraction 
efficiency; the amount of surrogate matrix required for method validation, an appropriate 
calibration strategy, and how to quantify DOX without internal standard correction. In the 
present study homogenized lamb’s lungs were used as a surrogate matrix in order to develop 
and validate an ex vivo SPME method that can precisely quantitate doxorubicin levels in 
tissue. Furthermore, several analytical considerations related to the optimized method’s ability 
to achieve fast in vivo extraction of DOX and near real-time monitoring of its levels and 






2. Materials and methods 
2.1. Chemicals and materials 
 The standard of doxorubicin (DOX) was purchased from Toronto Research Chemicals 
(Toronto, ON, Canada). The standard solution was prepared in water at a concentration of 
1000 µgmL
-1
 and stored in a glass vial at -80ºC. Fresh working solutions of DOX in water 
were prepared before each experiment. 
 Formic acid (FA), sodium chloride, potassium chloride, potassium phosphate 
monobasic, and sodium phosphate dibasic were purchased from Sigma Aldrich (Oakville, 
ON, Canada). LC-MS-grade acetonitrile (ACN), methanol (MeOH), and water were 
purchased from Fischer Scientific (Fair Lawn, NJ, USA). SPME-biocompatible mixed-mode 
(MM) fibers (coating: 45 µm thickness, 15 mm length) were generously provided by Supelco 
(Bellefonte, PA, USA). A phosphate-buffered saline solution (PBS) with a pH of 7.4 was 
prepared according to Reyes-Garces et al [32]. Lamb’s lungs, which were used as the 
surrogate matrix, were purchased in a grocery store, homogenized, and stored at -80ºC. 
Briefly, 250 g of tissue were cut in small pieces and mixed with dry ice. The mixture was 
added in a blender for homogenization. The homogenized samples were spiked, mechanically 
agitated for an initial 5 minute period followed by another 2 hours at 500 rpm, and then stored 
at 4°C overnight in order to bind and properly diffuse the analytes over the tissue. The 
following day, the samples were again agitated at 500 rpm for 2 hours prior to SPME 
extraction. 
2.2. Pig lung biopsies 
 Lung biopsies containing DOXO at unknown concentrations were obtained via in vivo 
lung perfusion (IVLP) procedures performed on pigs at the Toronto General Hospital 
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(Toronto, ON, Canada) and were kept frozen at -80ºC until extraction. Before the 
experiments, the samples were thawed and equilibrated to room temperature. The biopsies 
corresponded to different IVLP procedures at different sampling time. Sample 1 was taken at 
the middle of the procedure (2 hours), the concentration of doxorubicin in perfusate was 75 
mg/m
2 
and the total perfusion time was 4 hours. In sample 2, the biopsy was taken at the end 
of the procedure after flushing the lungs with perfusion solution without doxorubicin. The 
concentration of doxorubicin in perfusate was 75 mg/m
2
 and the total perfusion time was 2 
hours. Finally, Sample 3 was taken at the middle of the procedure (2 hours), the concentration 
of doxorubicin in perfusate was 150 mg/m
2
 and the total perfusion time was 4 hours. This 
study was approved by the University of Waterloo Office of Research Ethics (AUPP # A-16-
07 and ORE # T-1608-5). 
2.3. SPME method development 
2.3.1. SPME procedure 
 The optimization of the SPME procedure was performed in PBS solution and used 
homogenized lamb’s lungs as a surrogate matrix. Before use, the fibers were sterilized via 
steam autoclaving (Market Forge, Steamatic STM-E type C, VT, USA) at 121ºC for 40 min. 
Next, the sterile fibers underwent preconditioning in 300 µL of a acetonitrile/water mixture 
(80:20, v/v) for 60 min at 1500 rpm agitation. This was followed by 20 min of extraction 
under static conditions in either 0.3 mL of standard PBS solution or 15 g of homogenized 
lamb’s lung spiked with DOX. After sampling, the fibers were cleaned with a Kimwipe to 
remove any remaining matrix components from the coating, and they were then put through 
an additional cleaning stage consisting of vortex agitation in 300 µL of nanopure water for 10 
sec. Finally, the final extracts for LC-MS/MS analysis were obtained by immersing the fibres 
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in 300 µL of acetonitrile/water (80:20, v/v) with 0.1% formic acid for 60 min desorption at 
1500 rpm agitation. 
2.3.2. Extraction time profile 
 Extraction time profiles of DOX were performed to determine the kinetic of 
extraction, equilibration time, and optimum extraction time for ex vivo/in vivo SPME 
sampling from lung tissue. Sterile fibres were used to perform extractions from 15 g of 
homogenized lamb’s lung spiked with DOX at a concentration of 25 µg·mL
-1
. Extractions 
were performed in triplicate at intervals of 5, 10, 15, 20, 30, 60, and 120 min. The 
preconditioning, rinsing, and desorption steps were performed using the same methods and 
conditions described above. 
 
2.3.3. Method validation 
 Three different homogenized lamb’s lungs were used for the validation experiments. 
The first validation step was to evaluate the method’s specificity. Hence, SPME was applied 
to homogenized blank lamb’s lungs (blank samples) to test for potential interferences in DOX 
retention time. The limit of quantification (LOQ) was calculated as the concentration at which 
the signal-to-noise ratio (S/N) was ≥ 10 and the accuracy and precision are better than 80-
120% and 20%, respectively. Precision and accuracy were determined in three replicates at 
three validation levels: 10, 25, and 50 µg·mL
-1
. The method’s precision was given as a 
percentage of the relative standard deviation (RSD), and the method’s accuracy was given as a 
percentage of the bias against the nominal concentration. The validation point concentrations 
were back-calculated using three separated calibration curves from different lung samples in 
order to also prove the inter-animal reproducibility. Linearity was evaluated at 6 different 
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DOX concentrations, with independent triplicates ranging between 2.5 to 50 µg·mL
−1
. 
Extraction efficiency was expressed in mass units, while recovery was presented as a 
percentage expressing the amount of analyte extracted from the total sample by the coating. 
For instrumental calibration, the DOX standard was prepared by directly diluting the analyte 
standard stock solution in desorption solvent. Relative matrix effect was measured as 
the %RSD of the calibration curve slopes for the three different lungs. 
 
2.4. Ex vivo SPME sampling for determination of DOX level from intact (non-homogenized) 
and homogenized pig lung samples 
 Ex vivo sampling was conducted using three non-homogenized lung biopsies 
containing DOX. Pig lung biopsies were obtained from IVLP experiments performed at the 
Toronto General Hospital. Static extraction was performed by inserting the fibers into intact 
tissue for 20 min. The experimental details of the SPME methodology are described above. 
After extraction, the lung samples were homogenized and the entire SPME procedure was 
repeated in order to compare extraction efficiency between the non-homogenized and 
homogenized tissue. If the extract concentration of DOX was over the reported linear range, 
they were diluted to fit in the matrix matched calibration curve. It must to be noted that the 




2.5. Solid-liquid extraction (SLE) 
 In order to validate the SPME methodology against the gold standard technique,  
solid-liquid extraction, the samples were analyzed using a slightly modified version of an SLE 
method that was developed and validated by Kümmerle et al. [14]. The tissue was 
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homogenized by mixing it with dried ice in a mortar. Then, 0.1 g of lung tissue was weighted 
and mixed with 400 µL of an ACN/water mixture (40:60 v/v) with 0.1 % FA. The mixture was 
vortexed for 30 sec, which was followed by agitation for 10 min at 1500 rpm. After this step, 
the samples were centrifuged for 10 min at 15000 g while the temperature was kept constant 
at 4°C. The supernatant was then collected and analyzed by LC-MS/MS. When the extracts 
corresponded, they were diluted to fit the instrumental calibration curve. For quantitation, a 
matrix matched calibration curve in the range within 2.5-50 µg·g
-1 
was prepared following 
exactly the same sample preparation steps than the samples. 
 
2.6. LC-MS/MS analysis 
 Experiments were performed on an LC-MS/MS system consisting of a UHPLC with a 
Thermo Dionex UltiMate 3000 autosampler that was coupled via heated electrospray (H-ESI) 
to a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Scientific, San Jose, UA). 
Chromatographic separation was performed using a C18 column (Kinetex Phenomenex, 4.6 
mm × 150 mm, 3 µm particle size). The flow rate was set at 500 µL·min
-1
. Mobile phase A 
consisted of water with 0.1% formic acid, and mobile phase B consisted of acetonitrile with 
0.1% formic acid. The solvent gradient was set at a starting condition of 90% A from 0 to 1.0 
min and declined linearly to 10% A from 1.0 to 6.0 min. Finally, the solvent composition was 
reconstituted to 90% of A and held there until 10.0 min for re-equilibration. The total run time 
was 10 min at 20°C, and the total injection volume was 10 µL. The H-ESI conditions were 
1200 V for spray voltage, and 45, 13, 1 arbitrary units for sheath gas, auxiliary gas, and sweep 
gas, respectively. The vaporizer temperature was set at 358°C, and the ion transfer tube 
temperature was set at 350°C. Regarding MS detection, all analyses were performed in 
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positive ionization mode. The monitored transition for DOX was 544.1 to 361.0, which was 
achieved using a collision energy of 24.2 V. Furthermore, the dwell time was set at 50 msec, 
the RF lens was set at 66 V, and the CID gas level was set at 2 mTorr. The resolution of both 
the first and third quadrupole was 0.7 (FWHM), and the analyte was tuned in the instrument 
via external infusion of the standard at a concentration of 1 µg·mL-1.Under this conditions, the 
instrumental LOD for DOX was 0.01 ng. MS data were processed with XCalibur software 
v.4.0. (Thermo Fisher Scientific, San Jose, USA). 
 
3. Results and discussion 
3.1. Development of SPME method 
 An in vivo SPME method for extracting and monitoring DOX levels in human lungs 
during administration via IVLP requires the development of a robust procedure under 
laboratory conditions (ex vivo SPME). To this end, several parameters that could potentially 
influence the extraction efficiency during ex vivo/in vivo studies (e.g., selection of optimal 
preconditioning and desorption solvents, fiber sterilization, and sample volume) were 
evaluated. Comprehensive optimization that considers all conceptual aspects related to SPME 
and in vivo conditions is crucial in evaluating the methodology’s validity for further human 
studies. 
 The application of SPME in live human tissue requires a sterile environment, 
including the use of sterile fibers. However, the efficient extraction of a drug via such fibers 
has not been explored vis-a-vis biocompatible mixed mode fibers. Therefore, prior to the 
standard SPME protocol, the fibers were sterilized by steam autoclaving for 40 min. After 





), and the results were compared to those of the typically used non-
autoclaved fibers. As can be seen in Fig.1a, the autoclaved fibers provided about a 75% better 
extraction efficiency than the non-autoclaved fibers. The t-test comparison between both 
conditions give significant differences (p=0.02).One hypothesis for this result is that the 
autoclaving step is a more exhaustive conditioning procedure. This hypothesis is plausible, as 
a more exhaustive conditioning procedure will lead to the activation of more of the fibre’s 
surface area and, consequently, greater coating extraction capacity.  
 In SPME method development, it is crucial to select an appropriate combination of 
solvents for coating preconditioning prior to sampling and for desorbing the analyte from the 
coating after sampling, as this can greatly influence extraction efficiency. The mixtures tested 
for preconditioning were MeOH/water (50:50, v/v), ACN/water (80:20, v/v), and 
ACN/MeOH/water (40:40:20, v/v/v). Fig. 1b shows the area of DOX recovered from PBS as 
a function of the preconditioning strategy. The ACN/water mixture (80:20, v/v) provided 
higher efficiency in comparison to the MeOH/water mixture (p=0.04) and comparable results 
to the ACN/MeOH/water. Nevertheless, considering that the ACN/water mixture gave the 
lowest %RSD, the latter was selected as the optimal preconditioning mixture. Next, 
desorption solvent solutions were tested to find one that could completely desorb the analyte 
from the coating. Various combinations of solvents, including those used in the 
preconditioning step, were evaluated, with the mixtures containing ACN and water providing 
the best results (data not presented). Finally, two ACN/water mixtures with ratios of 50:50 
(v/v) and 80:20 (v/v) were tested to determine the optimal desorption solvent. After 60 min 
extraction in PBS, the 80:20 (v/v) ACN/water mixture proved to provide better desorption 
efficiency than the 50:50 (v/v) ACN/water mixture (Fig.1c). Furthermore, adding FA at a 
concentration of 0.1% (v/v) to the optimum desorption solution significantly improved both 
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the amount of analyte recovered and the %RSD. The latter was corroborated by a F-test which 
gave significant differences between variances (P=0.03). Furthermore, these experiments 
allowed us to select the 80:20 (v/v) ACN/water solution with 0.1% FA as the optimum final 
mixture, as it demonstrated less than 1% carryover on the fiber after the first desorption step 
(Fig. 1d). This improvement can be explained as a function of the pH wherein the acidity 
constant (pKa) shifts in the presence of solvents [33–35]. Hence, although the DOX amine 
group’s pKa is 8.2 in pure water [33,36,37], it shifts towards a more acidic pKa in a mixture 
with high ACN content. For instance, given that DOX has an amine pKa of 7.21 in a solution 
with an ACN composition of 50% (v/v) [33], its pKa will be even more acidic in the optimal 
desorption solution (ACN/H2O, 80:20, v/v). Therefore, the analyte will be desorbed in its 
neutral form, which reduces efficiency due to the desorption mixture’s high polarity. On the 
other hand, adding 0.1% FA to the desorption mixture keeps DOX fully charged and promotes 
efficient desorption from the coating to the solution. 
3.2. Considerations for in vivo SPME  
 This section details the practical and fundamental considerations involved in selecting 
the most feasible surrogate matrix. In addition, this section identifies and details the ex vivo 
SPME method that most closely reflects the in vivo SPME extraction conditions. One of the 
most important features of SPME under equilibrium conditions is the independence of the 
volume of the sampled tissue, but this assumption is only valid when the product between the 
fiber’s constant and volume (Kfs·Vf) is much lower than the volume of the sample (Vs) (Kfs·Vf 
« Vs) [22,25]. Given this, it is crucial to select the optimal amount of homogenized tissue for 
DOX extraction for two reasons: first, it enables the independence of the tissue volume’s 
influence on extraction efficiency; second, it enables extraction from the external matrix to be 
comparable to sampling a whole organ or living system. As it is impossible to collect enough 
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human lung tissue for this kind of experiment, lamb’s lung, which was relatively easy to 
access, was selected as the optimal surrogate matrix for ex vivo studies. As shown in Fig.2, 
homogenized lung tissue with DOX at a concentration of 25 µg·mL-1 in the range within 0.7 g 
to 30 g does not evidence a clear increasing. In addition, an ANOVA study of the 
experimental points gave no statistical differences within the range. However, in order to use 
a representative amount of tissue, 15 g of the homogenized surrogate lung was selected for ex 
vivo studies to reproduce an in vivo sampling.  
 Next, a calibration method under equilibrium conditions, independent of the 
hydrodynamic variables, was selected. It is critical to note that some blood-flow-related 
convection is generated when the fiber is inserted into a living system, which promotes faster 
extraction than under static conditions. Thus, using the static ex vivo extraction as a reference, 
it becomes apparent that equilibrium is always reached faster during in vivo extraction. This 
phenomenon is attributable to internal convection in the living system, which results in 
shorter equilibration times in real samples. Given this, the extraction time profile was 
obtained in static conditions for three lamb lungs using three independent autoclaved fibers 
for each time point. As indicated in Fig. 3, 20 min was the minimum extraction time required 
to reach equilibrium extraction, to attain maximum SPME sampling sensitivity. Furthermore, 
under equilibrium conditions the error in the determination decreased dramatically—more 
precisely, %RSD≈ 14% for inter-sample analysis (see Fig. 3). This is mainly attributable to 
the fact that, under equilibrium conditions, the only important factor is the coating’s affinity 
with the free analyte concentration, which remains practically invariable over different 
samples[22]. In contrast, shorter extraction times (below 15 min) appeared to be linear, 
diffusion-based extractions. In these extractions, several factors in the analyzed matrix, such 
as blood flow, fluid content, and tissue consistency, may have affected and modified the 
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amount of extracted drug. The interaction of these factors could potentially increase errors in 
determining the %RSD ≈ 40% values for inter-sample analysis. Kinetic calibration 
approaches also need to be excluded from the current study for the following reasons: (1) the 
lack of the ability to use internal standard correction for DOX extraction during in vivo 
studies in living humans (e.g. any compound can be neither administered nor loaded in the 
fiber as internal standard) [16,38]; and (2) they allow for the potential instability of 
experimental conditions during the IVLP (e.g. perfusate flow, leakage, medical interventions). 
This instability makes it impossible to perfectly control the variables that generate the 
boundary layer [29,39] required in the diffusion-based model. 
 Moreover, during the development of the SPME method for the quantitation of a drug 
in a solid tissue, the obvious physical differences between intact and homogenized tissues 
must be considered/taken into account. Fig. 4 shows the amount of DOX extracted from intact 
tissue and homogenized tissue for two different human lung samples (biopsies). As can be 
seen, there are no statistical differences between the two extractions at two different 
concentration levels under the aforementioned equilibrium conditions. 
 To summarize, extraction at equilibrium conditions is the most reliable strategy 
because it prevents matrix conditions from influencing SPME’s quantification capabilities in 
the absence of an internal standard. Since it takes several hours to administer doxorubicin in 
human studies [5], a sampling time of 20 min ensures that alternations in the level of the drug 
during chemotherapy can be monitored, and that a near-real-time profile of DOX 
biodistribution in the lung tissue throughout IVLP can be provided. Moreover, due to the 
minimal invasiveness of SPME probes vis-a-vis the living system, sampling can be performed 
several times in different parts of the lung without requiring the collection of terminal parts of 
the organ (tissue biopsy). Thus, the total analysis time, from the sampling step to the 
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assessment of the drug concentration, will be much shorter in comparison to the conventional 
steps of sample preparation (SLE) and analysis. 
 
3.3. Validation of SPME method 
 The developed SPME method was validated, and a detailed description of the 
experiments can be found in the experimental section of the manuscript. In order to assess the 
described method’s carryover, LOQ, linear dynamic range, accuracy, and precision, 
homogenized lung samples were spiked with doxorubicin at concentrations ranging from 2.5 
to 50 µg·g
-1
. It is important to highlight that, despite the extendibility of the linear dynamic 
range, this is the optimum condition for the further development of clinical research 
applications in humans. The procedure was successfully validated for three different lamb 




 ≥0.99) and an LOQ of 
2.5 µg·g
-1
, acceptable average precision (RSD<14.7%) and excellent accuracy (≈103.2) were 
also attained in the evaluated concentration range (see Table 1). Moreover, very good results 
in terms of relative matrix effects were obtained given that the slopes of the calibration curves 
constructed for the three different lamb lungs exhibited relative standard deviation (RSD) 
values of about 11%. The above results demonstrate that an ex vivo surrogate matrix model 
under equilibrium extraction conditions is suitable for the in vivo sampling and quantitation of 
DOX from human lungs during chemotherapy.  
 
3.4. Application of developed method for determination of DOX level in real lung samples 
 The optimized ex vivo SPME method was applied to quantify doxorubicin in real pig 
lung samples collected in different IVLP experiments at different time-points. The values for 
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the total DOX concentrations were calculated based on the assumption that the lamb lung 
used in the method optimization process had the same binding properties for the drug as a 
lung. First, non-homogenized lung samples were subjected to SPME sampling. Since the 
recovery of the micro-extractive methodology was below 0.01% (negligible depletion), the 
same tissue samples were then homogenized and SPME sampling was performed from 
prepared homogenates. Next, the quantitative results obtained by SPME in intact tissue and 
homogenized lung tissue containing DOX were compared to the results from the extraction 
performed using the traditional SLE method. Table 2 lists the concentrations attained using 
three different sampling approaches, and, as can be seen, no significant differences were 
observed. These results prove that SPME provides the same quantitation capabilities as 
regular SLE methods, while eliminating the need for sample homogenization or additional 
sample preparation steps. As can be evidenced from Table 2, the procedure number 3, which 
uses a dose of doxorubicin of 150 mg/m
2
, gave the highest tissue concentration in contrast to 
the procedure number 1 when the perfusate concentration was 75 mg/m
2
. It must be 
highlighted that despite this method was applied to biopsies, it could also be applied to in vivo 
sampling reducing dramatically the invasiveness of the procedure.   
In addition, as the ultimate goal is to attain precise assessments of DOX levels in different 
tissue compartments during in vivo sampling in the operating room, the developed method 
offers a promising solution that, to the best of our knowledge, cannot be achieved by any 
other technology at present.  
4. Conclusions 
 An analytical system based on ex vivo SPME sampling hyphenated to LC-MS/MS 
method was developed to accurately and precisely quantitate the level of the anticancer drug, 
doxorubicin, by direct sampling from lung tissue samples. The ex vivo SPME method was 
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validated for homogenized lamp lung samples used as the surrogate matrix. It exhibited 
excellent linearity (R
2
 ≥0.99) within the range of 2.5-50 µg·g
-1
, a LOQ of 2.5 µg·g
-1
, good 
precision (RSD<14.7%) and accuracy (≈103.2), and relative low matrix effect values of about 
11%. Besides, the method was validated analyzing pig lung biopsies taken from doxorubicin 
IVLP procedures. The concentrations reported, were cross-validated against a well-stablished 
LSE-LC-MS method. Due to the fact that ex vivo SPME extractions in lung tissue reach 
equilibrium, the entire procedure can be performed without the use of hydrodynamic controls 
and internal standard correction, enabling the methodology to be implemented in in vivo 
SPME sampling. However, it is important to highlight that the equilibration time strongly 
depends on the affinity constant. Thus, higher affinities increase equilibration times, which 
will lead to diminish the practicality of the stated approach. The optimized ex vivo SPME 
method will facilitate near to real-time monitoring of the concentration and biodistribution of 
DOX in the lung tissue of a living organism (in vivo SPME) during the treatment of cancer 
metastases in lungs (IVLP). Hence, SPME can be a powerful tool for therapeutic drug 
monitoring in clinical studies, because it can provide precise information about the delivery of 
the drug to the specific sites in the organ while also ensuring that the level of a drug in a 
patient’s tissue is safe. Such an approach may become an important part of personalized 
oncological treatment. Further experiments will focus on analyzing DOX in lung samples and 
perfusion solutions using the above described extraction method. However, these experiments 
will attempt to circumvent the chromatographic step, which will dramatically reduce the total 
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Figure 1. A) Comparison of extraction efficiency of doxorubicin between autoclaved and 
non-autoclaved fibers. Preconditioning and desorption of fibers was performed in ACN/water 
(80:20, v/v) and ACN/ water (80:20, v/v) with 0.1% FA (n=5). B) Optimization of SPME 
preconditioning step using three preconditioning solutions: MeOH/ water (50:50, v/v), ACN/ 
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water (80:20, v/v), and ACN/MeOH/ water (40:40:20, v/v/v) (n=5). C) Optimization of SPME 
desorption step of SPME using two desorption solutions (ACN/ water) ratios: 50:50 (v/v) and 
80:20 (v/v) (n=5). D) First and second desorption performed with and without the addition of 
0.1% FA to the optimum desorption solution (ACN/water, 80:20, v/v). Extraction of DOX at a 
concentration of 10 µg·mL-1 was performed from 300 µL of PBS for 10 min at 1500 rpm 
with the use of 15 mm length MM fibers (n=5). 
Figure 2. Comparison of the amount (ng) of DOX extracted from different amounts of 
homogenized lung tissue at a concentration of 25 µg·g
-1 
by four independent replicates; 20 
min static extraction from tissue was performed using 15 mm long autoclaved MM fibers 
(n=3).   
Figure 3. Overlapping of three static extraction time profiles of doxorubicin at 25 µg·g
-1
 
obtained from three different lamb lung samples (15 g of homogenized tissue). Each 
experimental point represents the average of 9 different and independent experiments from 
three lungs (3 fibers per lung per point). Conditions of extraction and analysis are detailed in 
the experimental section. 
Figure 4. Comparison of extraction efficiency between intact (non-homogenized) and 
homogenized lung tissue for two different pig lung biopsies (1 gram of tissue) after in vivo 
lung perfusion (IVLP) experiment with the administration of different doses of DOX: 150 
mg/m
2
 (Sample 1) and 75 mg/m
2
 (Sample 2). Static extraction was performed for 20 min 
using 15 mm long autoclaved MM fibers (3 fibers per assay). For desorption and analysis 




Table 1. Figures of merit for DOX quantitation using three homogenized lamb lung samples 
as a surrogate matrix. Least square linear regression has been applied to fit the experimental 
data points.  
Sample slope  intercept  R
2 LOQ 
Accuracy (n=3) Precision (n=3) 
10 µg·g
-1 25 µg·g-1 50 µg·g-1 10 µg·g-1 25 µg·g-1 50 µg·g-1 
Lung 1 0.0229 -0.06 0.9991 5 113.0 100.6 112.8 20.1 12.1 18.4 
Lung 2 0.0271 0.0077 0.9982 5 92.4 102.1 100.1 6.2 5.8 18.3 
Lung 3 0.0222 -0.008 0.9989 5 106.3 102.6 99.2 21.5 10.9 19.3 
 
Table 2. Table 2. Comparison of the quantitation capabilities of SPME probes in intact pig 
lung samples against ex vivo SPME homogenized samples and solid-liquid extraction. Lung 
tissue samples (n=3) were collected at the end of IVLP experiment with the administration of 
different dosed of DOX. Sample 1: 75 mg/m
2
, sample 2: 75 mg/m
2
 but post blank perfusion 
and, sample 3: 150 mg/m
2















Sample 1 167 (± 54) 170 (± 38) 165 (± 16) 
Sample 2 n/d n/d n/d 
Sample 3 530 (± 49)  519 (± 83) 539 (± 7) 
 
HIGHLIGHTS 
• A minimum invasive method for repeated sampling of doxorubicin from lung 
tissue was developed. 
• The SPME fiber is directly inserted in the tissue for minimally invasive 
extraction. 
• Extraction under equilibrium conditions without the use of internal standard 
correction. 
• SPME provides rapid and accurate information about drug level in different 
organ areas. 
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